Exploiting the Achilles' heel of membrane trafficking in trypanosomes by Zoltner, Martin et al.
                                                              
University of Dundee
Exploiting the Achilles' heel of membrane trafficking in trypanosomes
Zoltner, Martin; Horn, David; de Koning, Harry P.; Field, Mark
Published in:
Current Opinion in Microbiology
DOI:
10.1016/j.mib.2016.08.005
Publication date:
2016
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Zoltner, M., Horn, D., de Koning, H. P., & Field, M. C. (2016). Exploiting the Achilles' heel of membrane
trafficking in trypanosomes. Current Opinion in Microbiology, 34, 97-103. DOI: 10.1016/j.mib.2016.08.005
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 17. Feb. 2017
Exploiting the Achilles’ heel of membrane trafficking in
trypanosomes
Martin Zoltner1, David Horn1, Harry P de Koning2 and
Mark C Field1
Pathogenic protozoa are evolutionarily highly divergent from
their metazoan hosts, reflected in many aspects of their
biology. One particularly important parasite taxon is the
trypanosomatids. Multiple transmission modes, distinct life
cycles and exploitation of many host species attests to great
prowess as parasites, and adaptability for efficient, chronic
infection. Genome sequencing has begun uncovering how
trypanosomatids are well suited to parasitism, and recent
genetic screening and cell biology are revealing new aspects of
how to control these organisms and prevent disease.
Importantly, several lines of evidence suggest that membrane
transport processes are central for the sensitivity towards
several frontline drugs.
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African trypanosomes: novelty and
conservation
Trypanosomatids cause a very broad range of diseases
afflicting humans, animals, livestock, fish, plants and wild
animals. Evidence has emerged for preadaptation to
parasitism during evolution of the group and ongoing
genetic modifications to suit distinct modes of infection
and immune evasion [1,2]. Trypanosomes are classi-
fied as Excavata, and branched early from the eukaryotic
lineage [3]. This fuelled considerable optimism that
when the genomes of these organisms were characterized,
a wealth of drug and potential therapeutic targets would
emerge. Approximately forty percent of trypanosome
protein-coding genes appear either lineage-specific or
of such great divergence that they present a viable target,
despite having an ortholog in higher eukaryotes [4,5].
This promise has, however, failed to emerge for several
reasons, not least of which is translating initial hit com-
pound activity against specific protein targets to leads
with promising activity against whole cells, that is, try-
panocidal or trypanostatic activity. Consequently, many
efforts identifying new drugs remain focused on classical
approaches such as phenotypic screens and do not, at least
a priori, engage with either genetic divergence or those
cell biological aspects unique to the kinetoplastids [6].
Even compounds emerging from various screening
efforts, with promising in vitro activity have experienced
low rates of translation into viable (pre)-clinical candi-
dates. However, serendipitously, it has emerged that
many drugs presently used against these parasites, and
specifically the African trypanosomes, do target rather
well known unique aspects of trypanosome cell biology,
and/or require these features, for their specificity and high
potency.
The trypanosome cell is elongated, with a morphology
supported by a sophisticated and elaborate subpellicular
microtubule array [7,8]. This feature essentially precludes
budding of conventional transport vesicles from the vast
majority of the plasma membrane, and all membrane flow
to and from the surface is restricted to the flagellar pocket.
Thus, drugs that do not effectively diffuse across mem-
branes, must reach their intracellular targets via the
flagellar pocket or cross the membrane via an alternate
mechanism, that is, a transporter or channel. The flagellar
pocket crucially is devoid of the microtubule array, and
while the membrane is continuous with the bulk plasma
membrane, it has a distinct protein and lipid composition
and is physically delineated by a complex collar surround-
ing the pocket neck, which likely also restricts fluid phase
diffusion [8,9].
Trypanosomes possess a conventional endomembrane
system, including a Golgi complex, early and recycling
endosomes, late endosomes incorporating the ESCRT/
multi-vesicular body system and a terminal endosome or
lysosome, albeit somewhat streamlined, with several of
these organelles probably present in interphase cells as
single copy [10,11]. Several features are highly unique, for
example, the mammalian-infective form of T. brucei has
an extreme rate of endocytosis, capable of turning over
the plasma membrane many times per hour, contributing
towards removal of surface-bound immune effectors,
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aiding immune evasion [12]. The surface is dominated
by the variant surface glycoprotein (VSG), a GPI-an-
chored homodimer comprising 90% of surface protein.
Other surface proteins possess trans-membrane domains,
but, importantly, are often highly divergent and trypano-
some-specific [13,14].
Trypanosome endocytosis is exclusively clathrin-
dependent, setting it apart from higher eukaryotes where
multiple modes of endocytosis operate [15]. Furthermore,
the widely conserved heterotetrameric (AP)-2 adaptin
complex is absent and is inversely correlated with the
presence of VSG and thus antigenic variation, the princi-
pal mechanism of immune evasion [16,12]. Additional
clathrin adaptor proteins are present and include both
ENTH and ANTH-domain phosphoinositide-binding
proteins [17] and a cohort of trypanosomatid-specific
proteins [18]. Sorting surface trans-membrane proteins
requires ubiquitylation, likely performed by divergent
ubiquitin ligases, although these remain unidentified
[19]. Whilst these details indicate a distinct endocytic
system, the level of conservation with, for example,
Saccharomyces cerevisiae, is considerable and the diver-
gence certainly appears less extreme than in Apicom-
plexan parasites, where entire compartments and
pathways have been repurposed [20,21].
Membrane transport activity is rather different between
life stages and species of parasite, which may in part
explain the differential sensitivity to some front-line
drugs. Specifically, the bloodstream forms of T. brucei
have much greater endocytic transport rates compared
with the insect forms, and this correlates with sensitivity
to suramin and pentamidine for example, with procyclic
cells being much less sensitive to either drug, although
other changes to the surface composition are considerable
and may also contribute to the differential sensitivity.
Although pentamidine is almost exclusively used against
T. brucei gambiense, the West African form of the disease,
and suramin usually for the East African T. brucei rhode-
siense, both subspecies are fully sensitive to either drug.
Both drugs are used exclusively to treat early stage
(haemolymphatic) trypanosomiasis, because neither drug
penetrates sufficiently into the central nervous system; it
is not known how trypanosomes adapt after crossing the
blood–brain barrier, and whether this might impact drug
sensitivity.
In addition to endocytic mechanisms for entry into the
cell, trypanosomes also possess a considerable array of
surface nucleoside and nucleobase transporters, together
with hexose and amino acid permeases, plus a small
family of aquaporins [22]. These systems obviously also
present a potential mechanism for accumulation of drugs
as well as natural metabolites, whilst themselves also
being proteins that are subject to turnover by the endo-
cytic system. By contrast to many surface proteins, the
transporters appear to be more broadly conserved with
higher eukaryotes. Significantly, traffic focused at the
flagellar pocket, high rates of endocytosis, novel surface
protein composition and the presence of conserved trans-
porters all directly contribute towards sensitivity of
African trypanosomes to drugs that have been in clinical
use since the 1920s.
A grandfather therapeutic: suramin
Suramin emerged from early synthetic chemistry and
development of aniline dyes [23]. The trypanocidal diazo
dyes, trypan red and trypan blue, were developed by
Bayer in 1916 and led to suramin, still a frontline treat-
ment against some forms of trypanosomiasis [24]. High
molecular weight and negative charge prevent passive
membrane diffusion, suggesting specific uptake. A thou-
sand-fold reduced potency against insect stage parasites
suggested involvement of endocytosis, as endocytic traf-
ficking is much decreased in this life stage [25]. However,
extensive surface proteome remodelling between life
stages also suggests the possibility of bloodstream
stage-specific expression of a ‘suramin-receptor’ [14].
Genome-wide loss-of-function screens identified multi-
ple genes that sensitize trypanosomes to suramin [26]
(Figure 2), many of which have roles and/or locations at
the endocytic pathway, for example, invariant surface
glycoprotein 75 (ISG75), two deubiquitylating enzymes
(DUBs) Usp7 and Vdu1, the AP-1 adaptin complex and
the lysosomal protein p67 [27]. An ISG75-dependent
pathway is required for lysosomal delivery of suramin
while an AP-1-dependent path is likely connected to
lysosomal composition and a requirement for transport
of p67 and other factors (Figure 1) [19]. ISG75 stability
is regulated by ubiquitylation [28] and evidence that
trypanosome Usp7 and Vdu1 modulate ISG75 turnover
is consistent with this model [19]. Significantly, the
suramin-uptake pathway is highly specific and does not
involve the closely related invariant surface glycoprotein
65 (ISG65) family.
Together these observations are consistent with a hy-
pothesis that ISG75 is the suramin receptor, but failure to
demonstrate binding in vitro to recombinant ISG75 (un-
published data, MZ, MCF) suggests that additional fac-
tors may be involved. Suramin binds various serum
proteins with high affinity, including Low Density Lipo-
protein (LDL), and the influence of LDL on suramin
uptake has led to a proposed model of an LDL-depen-
dent receptor-mediated pathway for suramin internaliza-
tion [29]. However, this was overturned by the mutation
of trafficking pathway components [25]. Formal proof of
receptor identity and precise mechanisms for suramin
uptake remain elusive, but what is clear is the essential
role for endocytosis and a protein with an itinerary that
includes transport through the endosomal system. Signif-
icantly, the lysosomal proteases CatL and CBP1 are also
implicated for suramin-sensitivity, and potentially these
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proteases are required for degradation of ISG75 to release
suramin into the lysosome [30]. Notably, recent evidence
indicates that CatL also degrades human serum trypano-
lytic factors and that a lysosomal inhibitor of a cysteine
peptidase, modulates this protease activity [31].
Despite these advances the mechanism of suramin tox-
icity remains elusive. Suramin exhibits considerable poly-
pharmacology and can bind and inhibit a wide variety of
distinct protein families (see e.g. [32–34]). Although
suramin inhibits all seven trypanosome glycolytic
enzymes plus cytosolic pyruvate kinase (PYK) in the
micromolar range [35], it inhibits bloodstream stage try-
panosome proliferation at nanomolar concentrations
[26], making it unlikely that glycolysis represents the
primary target. However, endocytosis may accumulate
the drug to higher intracellular levels than the external
concentration; importantly the highly charged suramin
molecule, once internalized, cannot easily escape from
the cell. Again, this represents a remarkable impact from
unique aspects of trypanosome cell biology in enabling
specific toxicity, and is currently beyond the ability of
rational drug design to predict or replicate. However,
these features do indicate potential cellular aspects that
are exploitable.
Old and still in the clinic: pentamidine and
melarsoprol
Aromatic diamidine drugs including pentamidine, and
organic arsenicals like melarsoprol, are highly cytotoxic
to most cells they enter. Therefore toxicity is predomi-
nantly determined by uptake across the plasma mem-
brane, and selectivity rests on the expression of efficient
cell-surface transporters by the parasite. Conversely,
mutations in such transporters diminishing transport rates
or loss of substrate recognition can lead to drug resistance
[36]. Pentamidine and melarsoprol, despite very different
structures, exhibit cross-resistance in Trypanosoma brucei
[37]. Since pentamidine and melarsoprol have distinct
cellular targets, cross resistance may reside within the
Endocytosis and drug delivery in trypanosomes Zoltner et al. 99
Figure 1
Lysosome
Late
endosome
Golgi
Early
endosome
Flagellar
pocket
endosome
Recycling
Clathrin coat
apparatus Endoplasmic
reticulum
Deubiquitylation
Ubiquitylation
Exocytosis
ISG75 p67
Plasma membrane
Flagellar
pocket
collar
AQP1 AQP2 AQP3
ISG75 pathways
AP-1 pathway
ISG65
AQP2 pathways
Phosphorylation/
Dephosphorylation
Flagellar membrane/
p67
AQP2
AQP1
AQP3
AP-1
ISG75
ISG65
?
?
Current Opinion in Microbiology
The trypanosome endosomal system. A simplified schematic of the trypanosome endomembrane system is shown, with the flagellar pocket at top
left. Teal and orange arrows indicate degradative and recycling trafficking routes, blue putative AP-1-mediated transport from the Golgi complex
to the lysosome and gray exocytic/biosynthetic pathways. The predominant locations of ISG75, ISG65, aquaglyceroporins and p67 (the major
lysosomal protein) are indicated by icons. Evidence suggests that ISG75 is ubiquitylated at, or close to the surface (magenta) and deubiquitylation
by TbUsp7 and/or TbVdu1 is proposed to take place before the sorting step at the early endosome that selects for the recycling or degradative
arm of the endocytic system. TbVdu1 is known to associate with structures in this region, whilst TbUsp7 is likely cytosolic. AQP2 localization is
restricted to the flagellar pocket, while AQP1 and AQP3 are predominantly on the flagellar membrane and plasma membrane, respectively. AQP2
has been recently described as high-affinity pentamidine receptor and this raises the possibility of endocytotic uptake.
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uptake mechanism. An unusual aminopurine transporter,
TbAT1/P2, a member of the highly conserved Equili-
brative Nucleoside Transporter family, facilitates uptake
of both [37]. Deletion or mutation of the TbAT1/P2 gene
reduces the sensitivity of T. brucei to diamidines, particu-
larly diminazene, and melaminophenyl arsenicals [38–
42].
Significantly, loss of TbAT1/P2 alone does not recreate
the high levels of melarsoprol-pentamidine cross-resis-
tance (MPXR) observed [39,43]. T. brucei expresses addi-
tional transport systems for pentamidine and a genome
wide RNAi screen identified the TbAQP2/AQP3 locus as
the genetic determinant for MPXR [26,44]. Further
analyses revealed that aquaglyceroporin 2 (AQP2) deter-
mines MPXR [44,45]. Further, re-introduction of a
wild-type TbAQP2 allele in even the most resistant strains
fully restores drug sensitivity [45,46,47,41]. Indeed,
expressing TbAQP2 in Leishmania mexicana promastigotes
profoundly increases their sensitivity to both pentami-
dine and melarsoprol [45].
However, the translocation mechanism of TbAQP2 is less
obvious as aquaglyceroporins are not known to allow
passage of molecules of high molecular weight like mel-
arsoprol or pentamidine. TbAQP2 does have a unique
selectivity filter; several large, aromatic amino acids that
normally restrict the pore are replaced by smaller side
chain residues, and a key arginine is replaced with leucine
[44]. These changes are expected to enlarge the pore size
and thus allow passage of cations, including the highly
flexible pentamidine molecule [36]. However, an alter-
native model, in which AQP2 binds pentamidine and
mediates internalization via receptor-mediated endocy-
tosis, was recently proposed [48]. This is an attractive
alternative, marrying the implausibility of large-molecule
transport by TbAQP2, an unusually high affinity for
pentamidine, the high endocytosis of bloodstream trypa-
nosomes [12] and localization of TbAQP2 to the flagellar
pocket [44]. The flagellar pocket localization is consis-
tent with uptake by endocytosis (Figure 1). Thus, uptake
of both suramin and pentamidine, and potentially even
melarsoprol, may depend upon their affinities for surface
receptors, with subsequent membrane trafficking
(Figure 2).
The genes identified through genome-wide screens
[26] for pentamidine/melarsoprol and suramin sensitiv-
ity do feature a significant overlap but this does not
implicate common endocytic components. However, ad-
ditional evidence from these screens is consistent with
involvement of trafficking factors downstream of AQP2
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Mode of action of trypanocidal drugs. Summary of biochemical pathways linked to drug action for suramin, pentamidine and melarsoprol. Proteins
sensitizing to the respective drug, as identified in a genome-wide loss-of-function screen [26] are drawn in red. (Pi: inorganic phosphate, Ub:
ubiquitin).
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[26]. Indeed, for both pentamidine and melarsoprol, the
screens identified proteins likely involved in phosphor-
ylation (Phosphatase 2C) and ubiquitylation (Cullin1)
(Figure 2), post-translational modifications implicated
in regulating endocytosis of mammalian AQP [49]. This
is reminiscent of the DUBs that sensitize trypanosomes to
suramin and regulate ISG75 [19]. However, if these
proteins are involved in the promotion of AQP2 internal-
ization and turnover, knockdown could change pentami-
dine sensitivity regardless of whether the drug binds the
channel or translocates through it. Finally, the endocyto-
sis model does not explain all previous observations on
pentamidine uptake in T. brucei, such as a 10-fold higher
rate of high-affinity pentamidine uptake in procyclic
forms than in bloodstream forms [50] despite TbAQP2
distribution across the entire procyclic cell surface [44],
or the high uptake rate when TbAQP2 is expressed
in Leishmania promastigotes [45]. Both procyclic and
promastigotes have much lower endocytosis than the
bloodstream T. brucei [25,51], and further study is essen-
tial to settle the mechanism of TbAQP2-mediated drug
transport.
Perspectives
Serendipity will always be an important component of
discovery, and drug uptake is a good exemplar. Recognis-
ing the specific binding properties of aniline dyes to
fabrics in the early years of synthetic chemistry was
rightly interpreted as representing specificity, and ulti-
mately evolved into Ehrlich’s concept of the ‘magic
bullet’ that kills a pathogen but not the host. Ehrlich
also reported on the activities of trypan blue and trypan
red, two trypanocidal compounds leading to the develop-
ment of suramin. The unique features of the flagellar
pocket and high endocytic rate have long been considered
as potential routes to therapy and demonstrations that
innate immune mechanisms also rely on endocytic traf-
ficking has strengthened this [52]. Many experimental
interventions compromising endocytic trafficking lead to
the rapid death of African trypanosomes [53], and it is
rather a curious realisation that the properties of this
system were being exploited by highly effective thera-
peutic agents developed almost a century ago. There is
much scope for exploiting these drug uptake mechanisms
to deliver new drugs, especially given the surprising
variety of compounds that they internalize. Notably,
drug-loaded nanoparticles, coated with a nanobody spe-
cifically targeting the trypanosome surface, can be used to
bypass the usual delivery route altogether and deliver
drugs via endocytosis [47]. Indeed, this approach actually
increases the efficacy of pentamidine, and a similar ap-
proach is likely to be effective for delivering other drugs.
Harnessing these features represents attractive and trac-
table opportunities, as does direct screening for inhibitors
of the novel components that control trafficking and
surface protein transport. Finally, there are at least two
components required for trypanocidal activity, entry and
activity against a target; rather unexpectedly it is emerg-
ing that it is the former that may be more crucial for
specificity, at least for current drugs.
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